APA (7th ed.) Citation

Desmond Y. H. Yap, Jojo Hai, Paul C. H. Lee, Xueying Zhou, Michael Lee, Yu Zhang, . . . Xiaoxiang Chen. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Wiley.

Chicago Style (17th ed.) Citation

Desmond Y. H. Yap, Jojo Hai, Paul C. H. Lee, Xueying Zhou, Michael Lee, Yu Zhang, Meng Wang, and Xiaoxiang Chen. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HBM9161, a Novel FcRn Inhibitor, in a Phase I Study for Healthy Chinese Volunteers. Wiley, 2021.

MLA (9th ed.) Citation

Desmond Y. H. Yap, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HBM9161, a Novel FcRn Inhibitor, in a Phase I Study for Healthy Chinese Volunteers. Wiley, 2021.